- Home
- KLRS vs AAME Comparison
KLRS vs AAME Comparison
Compare KLRS & AAME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- AAME
- Stock Information
- Founded
- KLRS 2019
- AAME 1968
- Country
- KLRS United States
- AAME United States
- Employees
- KLRS N/A
- AAME N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- AAME Life Insurance
- Sector
- KLRS Health Care
- AAME Finance
- Exchange
- KLRS Nasdaq
- AAME Nasdaq
- Market Cap
- KLRS 46.0M
- AAME 46.3M
- IPO Year
- KLRS N/A
- AAME N/A
- Fundamental
- Price
- KLRS $3.71
- AAME $3.36
- Analyst Decision
- KLRS Strong Buy
- AAME
- Analyst Count
- KLRS 2
- AAME 0
- Target Price
- KLRS $23.00
- AAME N/A
- AVG Volume (30 Days)
- KLRS 689.3K
- AAME 47.2K
- Earning Date
- KLRS 11-15-2025
- AAME 11-11-2025
- Dividend Yield
- KLRS N/A
- AAME 0.60%
- EPS Growth
- KLRS N/A
- AAME N/A
- EPS
- KLRS N/A
- AAME 0.10
- Revenue
- KLRS N/A
- AAME $198,977,000.00
- Revenue This Year
- KLRS N/A
- AAME N/A
- Revenue Next Year
- KLRS N/A
- AAME N/A
- P/E Ratio
- KLRS N/A
- AAME $31.37
- Revenue Growth
- KLRS N/A
- AAME 6.98
- 52 Week Low
- KLRS $2.14
- AAME $1.25
- 52 Week High
- KLRS $24.15
- AAME $3.71
- Technical
- Relative Strength Index (RSI)
- KLRS 52.79
- AAME 63.86
- Support Level
- KLRS $2.37
- AAME $3.05
- Resistance Level
- KLRS $4.90
- AAME $3.35
- Average True Range (ATR)
- KLRS 0.70
- AAME 0.21
- MACD
- KLRS -0.02
- AAME -0.04
- Stochastic Oscillator
- KLRS 24.95
- AAME 46.21
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About AAME Atlantic American Corporation
Atlantic American Corp operates in specialty markets within the life and health and property and casualty insurance industries. The company has two segments: American Southern, It provides property and casualty insurance including bodily injury and property damage liability coverage, uninsured motorist coverage, and physical damage coverage for commercial accounts, and Bankers Fidelity, the company's life and health operations offer a variety of life and supplemental health products including ordinary and term life insurance, Medicare supplement, and other health insurance.